用于卵巢癌的溶瘤病毒疗法
Oncolytic virotherapy for ovarian cancer.
作者信息
Li Shoudong, Tong Jessica, Rahman Masmudur M, Shepherd Trevor G, McFadden Grant
机构信息
Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA.
Department of Anatomy and Cell Biology, University of Western Ontario, London, Ontario, Canada ; Translational Ovarian Cancer Research Program, London Health Sciences Centre, London, Ontario, Canada.
出版信息
Oncolytic Virother. 2012 Aug;1:1-21. doi: 10.2147/ov.s31626.
In the past two decades, more than 20 viruses with selective tropism for tumor cells have been developed as oncolytic viruses (OVs) for treatments of a variety of malignancies. Of these viruses, eleven have been tested in human ovarian cancer models in preclinical studies. So far, nine phase I or II clinical trials have been conducted or initiated using four different types of OVs in patients with recurrent ovarian cancers. In this article, we summarize the different OVs that are being assessed as therapeutics for ovarian cancer. We also present an overview of recent advances in identification of key genetic or immune-response pathways involved in tumorigenesis of ovarian cancer, which provides a better understanding of the tumor specificities and oncolytic properties of OVs. In addition, we discuss how next-generation OVs could be genetically modified or integrated into multimodality regimens to improve clinical outcomes based on recent advances in ovarian cancer biology.
在过去二十年中，二十多种对肿瘤细胞具有选择性嗜性的病毒已被开发为溶瘤病毒（OVs），用于治疗多种恶性肿瘤。在这些病毒中，有十一种已在临床前研究的人类卵巢癌模型中进行了测试。到目前为止，已经针对复发性卵巢癌患者使用四种不同类型的OVs进行了或启动了九项I期或II期临床试验。在本文中，我们总结了正在评估用于卵巢癌治疗的不同OVs。我们还概述了卵巢癌肿瘤发生过程中关键基因或免疫反应途径鉴定的最新进展，这有助于更好地理解OVs的肿瘤特异性和溶瘤特性。此外，我们根据卵巢癌生物学的最新进展，讨论了下一代OVs如何进行基因改造或整合到多模式治疗方案中以改善临床结果。
Zotero 插件